Orlando, FL (PRWEB) January 16, 2014
The birth control safety advocates at DrugRisk.com are now offering help to patients who have taken Yaz or Yasmin with questions about settlements. This is in addition to information on the site about the latest research, warnings and legal news on contraceptives like Yaz that use the hormone drospirenone.
DrugRisk is a free resource that provides updated information on the risks and benefits of prescription drugs and birth control. With data on Yaz, Yasmin, NuvaRing and Mirena IUDs, patients can find out if others are experiencing similar side effects and decide if they need legal advice.
The Yaz Center at DrugRisk has included health warnings from experts such as the British Medical Journal** and FDA*** that birth control pills containing the hormone drospirenone, like Yaz and Yasmin, can increase the risk of blood clots.
A number of patients have filed a Yaz lawsuit alleging side effects, leading cases to be relocated to a special federal court in Illinois (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois)). The latest court records obtained by DrugRisk show 9,826 Yaz claims were pending as of December 16*.
The new resource center will also offer the latest news on Yaz settlements. Bayer has spent nearly $1.575 billion so far to settle around 7,660 Yaz lawsuits alleging blood clot injuries like pulmonary embolism or deep vein thrombosis (DVT)****.
Anyone who suffered a blood clot, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin, or with questions about the ongoing settlements, is urged to visit DrugRisk or speak with a lawyer about their legal options.
Due to the specialized nature of federal drug injury litigation, DrugRisk only recommends lawyers who have already settled Yaz lawsuits.
For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
*Judicial Panel on Multidistrict Litigation, 12/16/13; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-December-16-2013.pdf
**BMJ, 10/25/11; ncbi.nlm.nih.gov/pubmed/22027398
***FDA, 10/27/11, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf
****Bayer Stockholder’s Newsletter, Explanatory Notes; Legal Risks, 10/31/13; stockholders-newsletter-q3-2013.bayer.com/en/explanatory-notes.aspx